BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Microlyvaq™ readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Microlyvaq™\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07285434-2622@assetmemo.bio
DTSTAMP:20261121T005326Z
DTSTART;VALUE=DATE:20280202
DTEND;VALUE=DATE:20280203
SUMMARY:Microlyvaq™: Phase 1 readout est. (NCT07285434)
DESCRIPTION:Microlyvaq™\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: C
 linical Study of the Therapeutic Effectiveness of In-silico-Designed\, Mac
 hine Learning Inspired\, and Quantum-molecularly Coupled Personalized Neoa
 ntigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell L
 ung Cancer\nEstimated primary completion: 2 February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/microlyvaq#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07285434
URL:https://assetmemo.bio/drug/microlyvaq#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
